Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Cervarix approved in China

July 18, 2016

OncBioMune Pharmaceuticals submits clinical protocol for ProscaVax in Mexico

July 18, 2016

Anti-endoglin MAb for Ewing sarcoma

July 18, 2016

Phase III GOYA trial of Gazyva in DLBCL misses primary endpoint

July 18, 2016

Juno Therapeutics acquires RedoxTherapies

July 15, 2016

ZIOPHARM plans phase I study of CD33 CAR T-cell therapy

July 15, 2016

Mologen enrolls first patient in phase I study for lefitolimod with ipilimumab

July 14, 2016

Servier gains worldwide license to Sorrento's anti-PD-1 antibody

July 13, 2016

AbbVie's ABT-414 wins rare pediatric disease designation from FDA

July 12, 2016

Leukemia & Lymphoma Society makes second investment in Kiadis to support development of ATIR-101

July 12, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...